1. Home
  2. CMPR vs BEAM Comparison

CMPR vs BEAM Comparison

Compare CMPR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cimpress plc (Ireland)

CMPR

Cimpress plc (Ireland)

HOLD

Current Price

$70.39

Market Cap

1.6B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$28.05

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPR
BEAM
Founded
1994
2017
Country
Ireland
United States
Employees
N/A
N/A
Industry
Publishing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CMPR
BEAM
Price
$70.39
$28.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
12
Target Price
$80.50
$48.09
AVG Volume (30 Days)
184.5K
1.6M
Earning Date
01-28-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.37
N/A
Revenue
$3,461,387,000.00
$55,701,000.00
Revenue This Year
$8.23
N/A
Revenue Next Year
$4.83
$26.52
P/E Ratio
$51.64
N/A
Revenue Growth
3.65
N/A
52 Week Low
$35.21
$13.53
52 Week High
$76.65
$35.25

Technical Indicators

Market Signals
Indicator
CMPR
BEAM
Relative Strength Index (RSI) 48.31 60.74
Support Level $69.87 $26.17
Resistance Level $74.49 $28.64
Average True Range (ATR) 2.35 1.39
MACD -0.51 0.08
Stochastic Oscillator 18.06 78.14

Price Performance

Historical Comparison
CMPR
BEAM

About CMPR Cimpress plc (Ireland)

Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: